---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-25-003611"
form_type: "8-K"
ticker: "NDRA"
cik: "0001681682"
company_name: "ENDRA Life Sciences Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:55:27.536393+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ENDRA Life Sciences Q4 net loss $4.2M, cash burn cut, pivots to GLP-1 metabolic health

## Summary
- Q4 2024 net loss $4.2M ($1.5M in Q4 2023) includes $2.3M non-cash inventory charge; full-year net loss $11.5M.
- Cash used in operations Q4 2024 $1.5M, down 32% YoY; expects ~$0.35M/month burn in Q2/Q3 2025.
- Cash and equivalents $3.2M at Dec 31, 2024; prior to pivot, runway limited given burn rate.
- New strategic direction: TAEUS as biomarker for monitoring GLP-1 drug patients, targeting pharma, concierge, primary care.
- Planned De Novo pivotal trial: multi-center, ~250 subjects, hypothesis-driven, with FDA pre-submission alignment.

## SEC filing metadata
- accession: 0001654954-25-003611
- form_type: 8-K
- ticker: NDRA
- cik: 0001681682
- company_name: ENDRA Life Sciences Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681682/000165495425003611/0001654954-25-003611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681682/000165495425003611/endra_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-25-003611
- JSON: https://secwatch.observer/filing/0001654954-25-003611.json
- Plain text: https://secwatch.observer/filing/0001654954-25-003611.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.